The lack of progress in the development of disease-modifying therapy in Alzheimer s disease (AD) was highlighted recently by the cessation of a phase 3 clinical trial studying the effects of bapineuzumab on mild to moderate disease.
No treatment benefit was apparent, whereas several serious side effects occurred more commonly in the treatment group compared to placebo.
.
